Phase 1/2 Study of UCART22 for Patients with Difficult-to-Treat CD22+ B-cell Acute Lymphoblastic Leukemia
Sponsor: Cellectis S.A.
ClinicalTrials ID:NCT04150497
This clinical trial is testing a new treatment called UCART22 for patients with B-cell Acute Lymphoblastic Leukemia (B-ALL) that has returned or not responded to previous treatments. The study aims to find out if UCART22 is safe and effective, and to determine the best dose for future studies.
Patient Parameters
| Parameter | Options |
|---|
Program Overview
This study is the first of its kind to test UCART22, a new treatment given through an IV, in patients with B-cell Acute Lymphoblastic Leukemia (B-ALL) that has either come back or not responded to other treatments. The main goals are to check the safety of UCART22, see how well it works, and find the best dose to use in future research.
Eligibility Criteria
Inclusion Criteria
- Have B-cell Acute Lymphoblastic Leukemia (B-ALL) with cancer cells that show the CD22 marker.
- Have B-ALL that has returned or not responded to previous treatments.
- Have already tried at least one standard chemotherapy treatment and one additional treatment after the first one didn't work.
Exclusion Criteria
- Have received any cellular therapy or experimental gene therapy within 60 days before joining the study.
Locations
| FACILITY | ZIP | CITY | STATE |
|---|---|---|---|
| University of California, Los Angeles (UCLA) - Medical Center | 90095 | Los Angeles | California |
| University of Colorado - Aurora Cancer Center | 80045 | Aurora | Colorado |
| Sarah Cannon - Colorado Blood Cancer Institute | 80218 | Denver | Colorado |
| University of Chicago | 60647 | Chicago | Illinois |
| Dana Farber Cancer Institute | 02215 | Boston | Massachusetts |
| Roswell Park Comprehensive Cancer Center | 14263 | Buffalo | New York |
| Memorial Sloan Kettering Cancer Center (MSKCC) David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center | 10021 | New York | New York |
| Weill Medical College of Cornell University | 10065 | New York | New York |
| Children's Hospital of Philadelphia | 19104 | Philadelphia | Pennsylvania |
| Sarah Cannon - HCA Research Institute | 37203 | Nashville | Tennessee |
Get This Program In Your Inbox
Receive detailed information about this treatment opportunity to review with your healthcare provider.